Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,403 across all filing types
Latest filing 2024-04-10 Regulatory Filings
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release dated April 10, 2024, announcing the presentation of preclinical efficacy data for a drug candidate (IPH45) at the AACR 2024 meeting. It details scientific findings, provides context about the drug and the company (Innate Pharma), and includes standard disclaimers and contact information. This format is characteristic of an initial announcement of scientific or operational news, rather than a comprehensive financial report (like 10-K or IR) or a formal regulatory filing like a proxy statement or dividend notice. Since it is an announcement of results/updates that is not a full financial report, it fits best under the general 'Regulatory Filings' (RNS) category as a broad corporate announcement, or potentially an 'Investor Presentation' (IP) if it were the presentation itself, but this is the press release *about* the presentation. Given the options, RNS serves as the best fit for a general corporate/scientific update press release that doesn't match a more specific category like ER or DIV.
2024-04-10 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated April 10, 2024, announcing preclinical efficacy data for a drug candidate (IPH45) presented at the AACR 2024 meeting. It details scientific findings, comments from the Chief Scientific Officer, and outlines the plan to move to clinical trials. This type of announcement, which releases key operational and scientific updates outside of mandatory periodic financial reports (like 10-K or IR), typically falls under a general regulatory announcement or an investor relations communication. Since it is not a full financial report (10-K, IR), a transcript (CT), a management discussion (MDA), or a specific capital event, it best fits the 'Regulatory Filings' (RNS) category as a general, time-sensitive corporate announcement, or potentially an Investor Presentation (IP) if it were the presentation itself, but this is the release *about* the presentation. Given the context of a press release announcing scientific data and future clinical plans, RNS is the most appropriate general regulatory/corporate update category.
2024-04-10 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated April 9, 2024, announcing that members of Innate Pharma's management team will be present at an upcoming investor conference (Van Lanschot Kempen conference) on April 16-17, 2024. This type of announcement, which details management's schedule for meeting with investors at industry events, is characteristic of Investor Presentation or Investor Relations activity, but specifically focuses on the *event* rather than a formal presentation document itself. Since the core purpose is to inform investors about management's availability at a conference, it aligns best with the 'Investor Presentation' (IP) category, which often covers management's forward-looking strategy and market positioning shared during such events, or it could be seen as a general investor relations update. Given the options, 'Investor Presentation' (IP) is the closest fit for an announcement detailing management's participation in an investor conference where they will discuss strategy and pipeline. It is not a formal report (10-K, IR), a transcript (CT), or a dividend notice (DIV). The document length is short (4670 chars), but it is not merely announcing the publication of another document, but announcing participation in an event.
2024-04-09 French
Inside Information / Other news releases
Report Publication Announcement Classification · 1% confidence The document is a press release dated April 9, 2024, announcing the company's (Innate Pharma) scheduled participation in an upcoming investor conference (Van Lanschot Kempen conference on April 16-17, 2024). This type of announcement, which details management's schedule for meeting with investors outside of formal earnings calls or regulatory filings, is typically classified as Investor Presentation (IP) material or an announcement related to investor relations activities. Since it is not a formal report (like 10-K or IR), nor a transcript (CT), nor a dividend notice (DIV), nor a management discussion (MDA), the most fitting category for an announcement detailing investor engagement activities is Investor Presentation (IP), as these events often involve presenting company strategy and pipeline updates to potential investors. Given the short length and the nature of the announcement (participation in a conference), it aligns best with investor-focused communication materials.
2024-04-09 English
Modalités de mise à disposition de document de référence ou de ses actualisations
Report Publication Announcement Classification · 1% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) and announces that the company has filed its 'Document d'enregistrement universel 2023' (Universal Registration Document 2023) with the AMF and its 'rapport annuel 2023 sur « FORM 20-F »' (Annual Report on Form 20-F) with the SEC. The text itself is an announcement about the availability of these official reports, not the reports themselves. Since it is an announcement regarding the publication of official reports (Universal Registration Document and Form 20-F), it fits the definition of a Report Publication Announcement (RPA). Although the 20-F is an Annual Report (10-K equivalent for foreign issuers), the document provided is the *announcement* of its filing, triggering the 'MENU VS MEAL' rule.
2024-04-05 French
Terms of availability of a registration document or its updates
Report Publication Announcement Classification · 1% confidence The document explicitly announces the filing of two major annual reports: the '2023 Universal Registration Document (DOCUMENT D'ENREGISTREMENT UNIVERSEL)' with the AMF and the '2023 Annual Report on Form 20-F' with the SEC. The Form 20-F is the standard SEC filing for foreign private issuers that serves as their annual report, equivalent to a 10-K for domestic issuers. Since the document is an announcement *about* the filing of these comprehensive annual reports, and its length is relatively short (5002 chars), it fits the definition of a Report Publication Announcement (RPA) rather than the full 10-K or AR document itself. The key indicator is the phrase 'Innate Pharma SA... today announced the filing of its 2023 Universal Registration Document... and 2023 Annual Report on Form 20-F.'
2024-04-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.